Items where authors include "Twelves, C."

Article

Pastorino, A., Liu, H., Pederson, L. et al. (22 more authors) (2025) The Definition of Cure in Colon Cancer. JAMA Oncology. ISSN 2374-2437

Goetz, M.P., Wander, S.A., Bachelot, T. et al. (8 more authors) (2025) ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1-mutated, metastatic breast cancer. Future Oncology, 21 (11). pp. 1317-1324. ISSN 1479-6694

Kristeleit, R., Basu, B., Miller, R. et al. (7 more authors) (2025) Corrigendum to ‘A Phase Ib, Open-Label Trial Of MOv18 IgE In Patients With Advanced Ovarian Cancer’ [International Journal of Gynecological Cancer Volume 35, Issue 2 Supplement 1 (2025) #809]. International Journal of Gynecological Cancer, 35 (5). 101893. ISSN 1048-891X

West, E.J. orcid.org/0000-0001-7449-120X, Sadoun, A., Bendjama, K. et al. (21 more authors) (2025) A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer. Clinical Cancer Research, 31 (7). pp. 1243-1256. ISSN 1078-0432

Hamilton, E., Oliveira, M., Turner, N. et al. (18 more authors) (2024) A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results. Annals of Oncology, 35 (8). pp. 707-717. ISSN 0923-7534

Hanna, D., Merrick, S., Ghose, A. et al. (24 more authors) (2024) Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom. British Journal of Cancer, 130 (12). pp. 1916-1920. ISSN 0007-0920

Braun, I.M., Bohlke, K., Abrams, D.I. et al. (12 more authors) (2024) Cannabis and Cannabinoids in Adults With Cancer: ASCO Guideline. Journal of Clinical Oncology, 42 (13). pp. 1575-1593. ISSN 0732-183X

Oswald, A.J., Symeonides, S.N., Wheatley, D. et al. (16 more authors) (2023) Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Research and Treatment, 199. pp. 35-46. ISSN 0167-6806

Liu, X., Munro, A.P., Feng, S. et al. (56 more authors) (2023) Corrigendum to “Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial” [J Infect 84(6) (2022) 795–813, 5511]. Journal of Infection, 86 (5). pp. 540-541. ISSN 0163-4453

Munro, A.P.S., Feng, S., Janani, L. et al. (362 more authors) (2022) Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. The Lancet Infectious Diseases, 22 (8). pp. 1131-1141. ISSN 1473-3099

Tripathy, D., Tolaney, S.M., Seidman, A.D. et al. (73 more authors) (2022) Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. JAMA Oncology, 8 (7). pp. 1047-1052. ISSN 2374-2437

Liu, X., Munro, A.P.S., Feng, S. et al. (56 more authors) (2022) Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. Journal of Infection, 84 (6). pp. 795-813. ISSN 0163-4453

Franzoi, M.A., Procter, M., Twelves, C. et al. (9 more authors) (2022) Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial. Ecancermedicalscience, 16. 1379. ISSN 1754-6605

Twelves, C., Bartsch, R., Ben-Baruch, N.E. et al. (6 more authors) (2022) The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC. Clinical Breast Cancer, 22 (3). pp. 223-234. ISSN 1526-8209

Abrams, D.I., Velasco, G., Twelves, C. et al. (2 more authors) (2021) Cancer Treatment: Preclinical & Clinical. JNCI Monographs, 2021 (58). pp. 107-113. ISSN 1052-6773

Saini, K.S., Punie, K., Twelves, C. et al. (6 more authors) (2021) Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics. Expert Opinion on Biological Therapy, 21 (7). pp. 945-962. ISSN 1471-2598

Coleman, R., Brown, J., Rathbone, E. et al. (9 more authors) (2020) CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON) : study protocol for a phase IB/IIA randomised controlled trial. Trials, 21 (1). 89.

Saini, K.S., Lanza, C., Romano, M. et al. (10 more authors) (2020) Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. British Journal of Cancer, 123. pp. 694-697. ISSN 0007-0920

Conference or Workshop Item

Lahu, G., Banerji, U., Tap, W.C. et al. (15 more authors) (2025) Abstract CT151: Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION® peptide drug conjugates. In: AACR Annual Meeting 2025, 25-30 Apr 2025, Chicago, Illinois.

Proceedings Paper

Basu, B., Miller, R., Iglesias, J. et al. (7 more authors) (2025) A Phase Ib, Open-Label Trial Of MOv18 IgE In Patients With Advanced Ovarian Cancer. In: International Journal of Gynecological Cancer. ESGO 2025 Congress, 20-23 Feb 2025, Rome, Italy. Elsevier .

Goetz, M.P., Wander, S.A., Bachelot, T. et al. (17 more authors) (2024) Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation. In: Journal of Clinical Oncology. 2024 ASCO Annual Meeting, 31 May - 04 Jun 2024, Chicago, USA. American Society of Clinical Oncology .

Banerji, U., Cook, N., Anthoney, A. et al. (11 more authors) (2024) Abstract CT188: A Phase I trial of AVA6000, a Fibroblast Activation Protein (FAP)-released and tumor microenvironment (TME)-targeted doxorubicin peptide drug conjugate in patients with FAP-positive solid tumors. In: Cancer Research. AACR Annual Meeting 2024, 05-10 Apr 2024, San Diego, USA. American Association for Cancer Research , ct188-ct188.

Jin, Z., Dixon, J.G., Parekh, H.D. et al. (17 more authors) (2020) Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database. In: Journal of Clinical Oncology. 2020 ASCO Annual Meeting I, 29-31 May 2020, Virtual. American Society of Clinical Oncology , p. 4099.

Cameron, D., Symeonides, S., Brunt, M. et al. (10 more authors) (2020) Abstract P3-11-09: ARISTACAT - Aromatase inhibition plus minus saracatinib as advanced breast cancer therapy: A randomised phase II study of aromatase inhibition plus/minus the Src-inhibitor AZD0530 in post-menopausal women with advanced breast cancer. In: Cancer Research. 2019 San Antonio Breast Cancer Symposium, 10-14 Dec 2019, San Antonio, Texas, USA. American Association for Cancer Research .

Preprint

West, E.J. orcid.org/0000-0001-7449-120X, Sadoun, A., Bendjama, K. et al. (21 more authors) (2024) A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancer. [Preprint]